| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Trisha Suppes, Hans Kroger, Andrei Pikalov, Antony Loebe. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of psychiatric research. vol 78. 2017-08-29. PMID:27089521. |
in this study, designed to evaluate the efficacy of lurasidone as adjunctive therapy with lithium or valproate, patients with bipolar i depression were randomized to 6 weeks of double-blind treatment with lurasidone (n = 180) or placebo (n = 176), added to background treatment with lithium or valproate. |
2017-08-29 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Elizabeth Dansie Bacci, Daisy Ng-Mak, Kathy Wyrwich, Andrei Pikalov, Antony Loebe. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC psychiatry. vol 16. 2017-08-08. PMID:27215976. |
effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. |
2017-08-08 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Elizabeth Dansie Bacci, Daisy Ng-Mak, Kathy Wyrwich, Andrei Pikalov, Antony Loebe. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC psychiatry. vol 16. 2017-08-08. PMID:27215976. |
the objective of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms) of lurasidone in improving patient hrqol. |
2017-08-08 |
2023-08-13 |
Not clear |
| Lindsay M Avery, Shannon J Drayto. Bipolar depression: Managing patients with second generation antipsychotics. International journal of psychiatry in medicine. vol 51. issue 2. 2017-06-30. PMID:27079776. |
in bipolar affective disorder, it is well known that patients spend a significantly greater amount of time in depressive episodes than manic or hypomanic episodes, yet there are currently just three food and drug administration-approved agents for the treatment of bipolar depression: (1) olanzapine/fluoxetine combination (2) quetiapine, both immediate- and extended-release, and (3) lurasidone. |
2017-06-30 |
2023-08-13 |
Not clear |
| Rafał R Jaeschke, Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Krzysztof Styczeń, Wojciech Datk. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological reports : PR. vol 68. issue 4. 2017-06-19. PMID:27203278. |
lurasidone is an atypical antipsychotic, approved by the us food and drug administration (fda) for the treatment of schizophrenia and bipolar depression. |
2017-06-19 |
2023-08-13 |
Not clear |
| Martha Sajatovic, Brent P Forester, Joyce Tsai, Hans Kroger, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. The Journal of clinical psychiatry. vol 77. issue 10. 2017-05-25. PMID:27529375. |
efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. |
2017-05-25 |
2023-08-13 |
Not clear |
| Martha Sajatovic, Brent P Forester, Joyce Tsai, Hans Kroger, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. The Journal of clinical psychiatry. vol 77. issue 10. 2017-05-25. PMID:27529375. |
the aim of this post hoc analysis was to evaluate the efficacy of lurasidone in patients aged 55 years and older with bipolar depression. |
2017-05-25 |
2023-08-13 |
Not clear |
| H Javelo. [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives]. Annales pharmaceutiques francaises. vol 74. issue 2. 2017-02-09. PMID:26472602. |
third-generation antipsychotics (aripiprazole, lurasidone, brexpiprazole, cariprazine) appear relevant in the treatment of resistant depression and some anxiety disorders. |
2017-02-09 |
2023-08-13 |
Not clear |
| Rona Jeannie Roberts, Kavita K Lohano, Rif S El-Mallak. Antipsychotics as antidepressants. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 8. issue 3. 2017-01-30. PMID:25963405. |
additionally, quetiapine and lurasidone have been approved for the treatment of bipolar depression. |
2017-01-30 |
2023-08-13 |
Not clear |
| Joseph Calabrese, Krithika Rajagopalan, Daisy Ng-Mak, Elizabeth D Bacci, Kathy Wyrwich, Andrei Pikalov, Antony Loebe. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. International clinical psychopharmacology. vol 31. issue 3. 2016-12-22. PMID:26717493. |
effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. |
2016-12-22 |
2023-08-13 |
Not clear |
| Joseph Calabrese, Krithika Rajagopalan, Daisy Ng-Mak, Elizabeth D Bacci, Kathy Wyrwich, Andrei Pikalov, Antony Loebe. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. International clinical psychopharmacology. vol 31. issue 3. 2016-12-22. PMID:26717493. |
short-term lurasidone monotherapy and adjunctive therapy is associated with a clinically meaningful improvement in hrqol in patients with bipolar depression. |
2016-12-22 |
2023-08-13 |
Not clear |
| Francesca Calabrese, Elisa Savino, Mariusz Papp, Raffaella Molteni, Marco A Riv. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacological research. vol 104. 2016-12-13. PMID:26742719. |
we believe that changes in clock genes expression after cms exposure may contribute to the disturbances associated with depressive disorders and that the ability of chronic lurasidone to normalize such alterations may be relevant for its therapeutic properties in ameliorating functions that are deteriorated in patients with major depression and other stress-related disorders. |
2016-12-13 |
2023-08-13 |
rat |
| Sunny Chapel, Yu-Yuan Chiu, Jay Hsu, Josephine Cucchiaro, Antony Loebe. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clinical therapeutics. vol 38. issue 1. 2016-09-14. PMID:26730454. |
lurasidone dose response in bipolar depression: a population dose-response analysis. |
2016-09-14 |
2023-08-13 |
Not clear |
| Sunny Chapel, Yu-Yuan Chiu, Jay Hsu, Josephine Cucchiaro, Antony Loebe. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clinical therapeutics. vol 38. issue 1. 2016-09-14. PMID:26730454. |
the goal of this pharmacometric analysis was to characterize the dose-response profile for lurasidone in patients with bipolar depression. |
2016-09-14 |
2023-08-13 |
Not clear |
| Leslie Citrom. Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient preference and adherence. vol 10. 2016-08-26. PMID:27563237. |
lurasidone is a second-generation (atypical) antipsychotic agent that is approved for the treatment of schizophrenia and bipolar depression. |
2016-08-26 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Kellie Meyer, Ken O'Day, Melissa Denno, Antony Loebe. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. Journal of medical economics. vol 18. issue 10. 2016-07-04. PMID:25985265. |
cost-effectiveness of lurasidone vs quetiapine extended-release (xr) in patients with bipolar depression. |
2016-07-04 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Kellie Meyer, Ken O'Day, Melissa Denno, Antony Loebe. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. Journal of medical economics. vol 18. issue 10. 2016-07-04. PMID:25985265. |
lurasidone and quetiapine extended-release (xr) are atypical antipsychotic agents indicated for monotherapy treatment of bipolar depression. |
2016-07-04 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Kellie Meyer, Ken O'Day, Melissa Denno, Antony Loebe. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. Journal of medical economics. vol 18. issue 10. 2016-07-04. PMID:25985265. |
the objective of this analysis was to estimate the cost-effectiveness of lurasidone and quetiapine xr in patients with bipolar depression. |
2016-07-04 |
2023-08-13 |
Not clear |
| Mark Sanford, Sohita Dhillo. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS drugs. vol 29. issue 3. 2016-06-13. PMID:25698146. |
lurasidone: a review of its use in adult patients with bipolar i depression. |
2016-06-13 |
2023-08-13 |
Not clear |
| Mark Sanford, Sohita Dhillo. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS drugs. vol 29. issue 3. 2016-06-13. PMID:25698146. |
lurasidone reduced the mean montgomery-Åsberg depression rating scale (madrs) total score from baseline (primary endpoint) by >50 %; the reductions in scores were significantly greater than with placebo. |
2016-06-13 |
2023-08-13 |
Not clear |